%0 Journal Article %T The Role of Pyridoxine in the Prevention and Treatment of Neuropathy and Neurotoxicity Associated with Rifampicin-Resistant Tuberculosis Treatment Regimens: A Topic Review %A Joseph G. Kariuki %A Symon M. Kariuki %A Phuti Angel %J Journal of Tuberculosis Research %P 33-48 %@ 2329-8448 %D 2023 %I Scientific Research Publishing %R 10.4236/jtr.2023.112004 %X Rifampicin-resistant tuberculosis (RR-TB) is a global public health problem caused by mycobacterium tuberculosis resistant to Rifampicin. Drug-induced peripheral neuropathy and neurotoxicity are well-known adverse effects of treatment regimens that cause significant morbidity. Pyridoxine is often added to treatment regimens for the prevention and/or treatment of these side effects. The basis and effectiveness of this practice are unclear. We conducted a systematic review to evaluate the effectiveness of pyridoxine in preventing and/or treating neuropathy and neurotoxicity associated with RR-TB treatment. We included studies with patients with RR-TB who experienced neuropathy or neurotoxicity attributed to RR-TB regimens and were given pyridoxine. Our findings showed contradicting evidence on the use of pyridoxine for preventing or treating neurotoxicity due to cycloserine in the treatment of RR-TB. Moreover, pyridoxine did not have a protective effect against neuropathy and/or neurotoxicity caused by other RR-TB regimens that do not contain isoniazid. In conclusion, we found that withdrawing or withholding medications such as linezolid, cycloserine, thioamides, fluoroquinolones, and ethambutol, implicated in causing neuropathy or neurotoxicity was more effective than using pyridoxine to stop the progression of symptoms, and in some instances, led to their reversal over time. %K Rifampicin-Resistant Tuberculosis %K Pyridoxine %K Vitamin B6 %K Neuropathy %K Neurotoxicity %K Multidrug-Resistant Tuberculosis %K Extensively Drug-Resistant Tuberculosis %U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=124825